The brain uptake index for vitamin E has not been reported previously. This study examined the pos sible involvement of altered brain vitamin E uptake as an explanation of alterations in vitamin E levels in the brain following I-methyl-4-phenyl-l ,2,3 ,6-tetrahydropyridine (MPTP) administration. The brain uptake index of vita min E was evaluated in control mice and at 1 and 24 h after toxin treatment. Control mice had a brain uptake Vitamin E is a highly lipophilic compound that is sequestered in cellular membranes where it func tions as a free radical scavenger and protects mem branes from lipid peroxidation. Vitamin E defi ciency is characterized by a neurological disorder resulting from neurodegeneration in the brainstem and other regions (Rosenblum et al., 1981) . Recent evidence has shown that vitamin E levels are al tered in the brain during Alzheimer's and Parkin son's diseases (Adams et al., 1991b). Similarly, mice treated with the parkinsonogenic neurotoxin 1-methyl-4-phenyl-1 ,2,3 ,6-tetrahydropyridine (MPTP) demonstrate alterations in brain vitamin E levels in several brain regions (Odunze et al., 1990) .
Summary: The brain uptake index for vitamin E has not been reported previously. This study examined the pos sible involvement of altered brain vitamin E uptake as an explanation of alterations in vitamin E levels in the brain following I-methyl-4-phenyl-l ,2,3 ,6-tetrahydropyridine (MPTP) administration. The brain uptake index of vita min E was evaluated in control mice and at 1 and 24 h after toxin treatment. Control mice had a brain uptake Vitamin E is a highly lipophilic compound that is sequestered in cellular membranes where it func tions as a free radical scavenger and protects mem branes from lipid peroxidation. Vitamin E defi ciency is characterized by a neurological disorder resulting from neurodegeneration in the brainstem and other regions (Rosenblum et al., 1981) . Recent evidence has shown that vitamin E levels are al tered in the brain during Alzheimer's and Parkin son's diseases (Adams et al., 1991b) . Similarly, mice treated with the parkinsonogenic neurotoxin 1-methyl-4-phenyl-1 ,2,3 ,6-tetrahydropyridine (MPTP) demonstrate alterations in brain vitamin E levels in several brain regions (Odunze et al., 1990) .
However, the uptake of vitamin E by the brain is poorly understood. The absorption and distribution of vitamin E have been reviewed (Bjorneboe et al., 1989) . Ingestion of vitamin E results in the gut up take of the vitamin in chylomicrons in the lymphatic index of 6.1 ± 1.2. The toxin induced more than a twofold increase in the vitamin E brain uptake index to 15.2 ± 6.8 at 1 h after treatment, which returned to control values at 24 h. The dramatic increase in the brain uptake index of vitamin E may explain the increases in vitamin E levels found in some brain regions following MPTP administra tion. Key Words: Brain uptake index-l-Methyl-4phenyl-l ,2,3,6-tetrahydropyridine-Vitamin E.
system. The chylomicrons are degraded in the liver with the release of vitamin E, which may then be incorporated into lipoproteins. These lipoproteins travel through the blood and probably represent the delivery form for vitamin E into the brain. The li pophilicity of vitamin E suggests that there should be no barrier to penetration into the brain for vita min E. However, the brain uptake of vitamin E has never been reported. This study investigated the brain uptake index of vitamin E in control and MPTP-treated mice.
MATERIALS AND METHODS
Male C57 BU6 mice (8 months old) were used in this study. MPTP was administered as the hydrochloride salt (Research Biochemicals, Natick, MA, U.S.A.) in saline, as four doses of 10 mg/kg i.p. given at 2-h intervals. This regimen has been shown previously to induce neuropa thology in the brain and blood-brain barrier in old mice (Adams et aI., 1991a) . Control mice were injected with four doses of saline. At 1 or 24 h after the last dose of MPTP, the brain uptake index of vitamin E was measured by the Oldendorf technique (1981) . Mice were anesthe tized with ketamine/xylazine to allow injection of ra diotracers into the right common carotid artery. 3H20 was used as a permeability standard. [14C]Vitamin E (Hoffmann-La Roche, Basel, Switzerland) was coin jected with the 3H20. Following digestion of the right brain, 3H and 14C were quantitated by liquid scintillation counting. Quench curves were made using control brain material to which 3H20 or [14C]vitamin E was added. Statistical assessment involved analysis of variance with the Newman-Keuls test. Table 1 demonstrates that the brain uptake index for vitamin E more than doubled in mice 1 h follow ing MPTP treatments. This may explain why some brain regions in MPTP-treated mice have increased vitamin E levels (Odunze et aI., 1990) . The decrease in vitamin E reported in other brain regions may be due to oxidation of the vitamin by oxygen radical generation due to MPTP toxicity. The brain uptake index for vitamin E is surpris ingly small considering its lipophilicity. For in stance, lipophilic drugs can have brain uptake in dexes of 120 or 130 (Oldendorf, 1981) . These results may demonstrate that vitamin E is too lipophilic to penetrate the blood-brain barrier rapidly. In other words, vitamin E does not diffuse rapidly out of the lipoproteins that carry it in the blood. The blood transit time in the brain capillaries is too short to allow uptake of vitamin E. Receptors for lipopro teins have been postulated in brain capillaries. Per haps these receptors are in part responsible for the small uptake of vitamin E by control brain.
RESULTS AND DISCUSSION
The mechanism by which MPTP increases the uptake of vitamin E is unknown. However, MPTP may diminish or slow down blood flow through the brain by damaging endothelial cells (Adams et aI. , 1991a) . Slower blood flow may allow a longer tran sit time in brain capillaries. This would provide more time for vitamin E to dissociate from lipopro teins and be absorbed through the blood-brain bar- 15.2 ± 6.8a 24 h after MPTP (n = 6) 6.3 ± 3.9
Eight-month-old male C57 Bl/6 mice were treated with saline or I-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) (four doses of 10 mg/kg i.p. at 2-h intervals). At 1 or 24 h after MPTP treatments, the brain uptake index of [14C]vitamin E was as sessed in comparison to 3H20. Results are expressed as means ±
SD.
a Significantly different from controls and 24-h treated mice by analysis of variance with the Newman-Keuls test (p < 0.05).
rier. Alternatively, breakdown of the blood-brain barrier induced by MPTP may allow penetration of free or lipoprotein-bound vitamin E across the dam aged barrier. Bound vitamin E could then dissociate from the lipoprotein and cross brain membranes.
Disruption of the blood-brain barrier results in dif ferential penetration of molecules into the brain, with high molecular weight molecules penetrating less efficiently than low molecular weight molecules (Ziylan et aI. , 1984) . Therefore, even though the blood-brain barrier is damaged by MPTP, the pen etration of lipoprotein-bound vitamin E increases only by a factor of 2.
The poor penetration of vitamin E into the brain implies that vitamin E therapy for brain diseases may be inefficient. During MPTP toxicity, the up take of vitamin E increases significantly. However, even the increased brain uptake of vitamin E is small in comparison with the uptake of lipophilic drugs. It is possible that a window of lipophilicity exists in terms of brain penetration. Compounds that are lipophilic enough to bind to albumin may penetrate into the brain following dissociation from albumin. However, more lipophilic compounds that are transported with lipoproteins cannot efficiently penetrate into the brain perhaps due to inefficient dissociation from lipoprotein.
